A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Participants with Prostate Cancer Undergoing Radiation Treatment with Androgen Deprivation Therapy (ADT)

Inclusion Criteria

• Diagnosis of and currently undergoing treatment for prostate adenocarcinoma
• Receiving curative intent radiotherapy (XRT) for prostate cancer * (Notes: A. Post-operative radiotherapy [i.e., “adjuvant” or “salvage radiotherapy subsequent to prostatectomy] is allowed. B. Subjects receiving brachytherapy in addition to beam therapy are allowed; subjects receiving brachytherapy alone are not allowed. C. Subjects with oligometastatic prostate cancer receiving radiotherapy and androgen deprivation [ADT] with curative intent are eligible)
• Subjects will be enrolled within two weeks prior to and two weeks after the final fraction of radiotherapy
• Receiving androgen deprivation therapy (ADT) for a duration of >= 3 consecutive months as follows: * Gonadotropin-releasing hormone (GnRH) agonist or antagonist (medical castration), with or without an anti-androgen (i.e., bicalutamide, flutamide, nilutamide, etc.), OR * Bilateral orchiectomy (surgical castration)
• Technology requirement: candidates must have access to the internet
• Able to understand and willing to sign a written informed consent document
• Able to speak and understand English, in the opinion of the treating physician

Exclusion Criteria

• Significant concurrent medical or psychiatric condition that would interfere with the patient’s ability to abide by the study protocol or cooperate fully with the protocol requirements, including completion of survey and assessment
• Currently enrolled in, screening for, or expecting to enroll within the next six months in a treatment-based clinical trial. Registry and biorepository studies are allowed as they will not confound the results through interaction with the health care system like a treatment trial will.